Clinical Core

临床核心

• 批准号: 10385831
• 负责人: CYNTHIA M CARLSSON
• 金额: $ 62.85万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-05-01 至 2024-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10385831
• 关键词: Adult; Advocacy; Aging; Alzheimer' s Disease; Alzheimer' s disease pathology; Alzheimer' s disease risk; Alzheimer’s disease biomarker; Amyloid; Autopsy; Awareness; Biological; Biological Markers; Biopsy; Blood; Blood Vessels; Blood specimen; Brain; Caring; Cell Line; Cerebrospinal Fluid; Clinical; Clinical Data; Clinical Services; Clinical assessments; Cognitive; Cognitive aging; Collaborations; Collection; Communities; Consent; DNA; DNA Markers; Data; Data Collection; Data Reporting; Data Set; Dementia; Development; Diagnosis; Discipline; Disease; Early Diagnosis; Early Intervention; Education; Ensure; Faculty; Family; Funding; Genetic; Goals; Grant; Impaired cognition; Individual; Infrastructure; Liquid substance; Longitudinal cohort; Magnetic Resonance Imaging; Medical; Memory; Mission; Nerve Degeneration; Neurobehavioral Manifestations; Neuropsychology; Participant; Pathologic; Patients; Persons; Pharmaceutical Preparations; Phenotype; Plasma; Population Control; Positron-Emission Tomography; Quality of Care; Recording of previous events; Recruitment Activity; Research; Research Personnel; Resources; Risk; Risk Assessment; Scientist; Services; Skin; Standardization; Statistical Models; Time; Training; Translational Research; Treatment Efficacy; Underrepresented Minority; Underrepresented Populations; Wisconsin; Work; base; brain health; cell repository; clinical biomarkers; clinical center; clinically relevant; cognitive change; cognitive testing; cohort; data management; data resource; data sharing; data standards; dementia care; dementia risk; dual diagnosis; education research; efficacy evaluation; ethnic diversity; experience; implementation facilitation; induced pluripotent stem cell; lifestyle factors; middle age; mild cognitive impairment; minority communities; neuroimaging; neuropathology; next generation; novel; outreach; pre-clinical; predictive marker; prevent; racial diversity; recruit; research clinical testing; social health determinants; tau Proteins; tool

PROJECT SUMMARY - CLINICAL CORE (CORE B) The primary objective of the Wisconsin Alzheimer's Disease Research Center's (ADRC) Clinical Core is to provide investigators access to well-characterized, diverse patient and control populations and high-quality, standardized clinical, cognitive, cerebrospinal fluid (CSF), serum/plasma, DNA, and neuroimaging data to facilitate translational Alzheimer's disease (AD) research in preclinical diagnosis and early intervention. To that end, the Core conducts comprehensive clinical evaluations in patients with mild cognitive impairment (MCI) and mild dementia due to AD, cognitively normal older controls (OCN, >65 years), and middle-aged adults (IMPACT cohort, 45-65 years) with varying levels of dementia risk based on family history. The Clinical Core team works closely with all Cores to facilitate the Center's mission by participating in outreach and recruitment activities to diverse communities; conducting standardized clinical and cognitive assessments of Core participants; gathering ancillary aging-related cognitive and clinical data, including a detailed vascular risk assessment; collecting high- quality blood, CSF, and DNA biospecimens; coordinating biospecimen collection with neuroimaging; completing standardized data reporting in a timely manner; conducting skin biopsies for acquisition of induced pluripotent stem cell (iPSC) lines; consenting Core participants for brain autopsy; facilitating cognitive testing and CSF collection within investigator-initiated studies; and ensuring timely availability of participants, data, and biospecimens to researchers locally and beyond. In the next grant cycle, the Core will accomplish the following aims: Aim 1: Continue to recruit and retain cognitively unimpaired adults (IMPACT and OCN) and patients with MCI for detailed annual (MCI, OCN) or biennial (IMPACT) clinical assessments (including standardized Uniform Data Set [UDS] data and blood samples) and for biennial (MRI, CSF) and baseline (PET in subset) biomarker assessments to support translational research in preclinical dementia. Aim 2: Continue to recruit and retain patients with mild dementia due to AD for detailed annual clinical and blood biomarker assessments (including standardized UDS data) and optional additional baseline biomarker assessments (MRI, CSF, PET). Aim 3: Continue to integrate culturally-tailored outreach, education, and clinical services to diverse communities to raise awareness of brain health and encourage long-term research engagement (including clinical and biomarker assessments) and advocacy in underrepresented minority communities. Aim 4: Continue to obtain consents for brain donation to support clinical-pathologic research and collect CSF, blood, DNA, and iPSCs for translational research on preclinical markers of MCI and AD dementia. Aim 5: Continue to provide infrastructure, resources, and services to facilitate collaborative research in normal cognitive aging, preclinical dementia, and dementia due to AD and expedite sharing of data and resources with the National Alzheimer's Coordinating Center, National Cell Repository for Alzheimer's Disease, and other AD Centers and investigators.

项目摘要 - 临床核心（核心 B） 威斯康星阿尔茨海默病研究中心 (ADRC) 临床核心的主要目标是 为研究人员提供了解特征明确、多样化的患者和对照人群以及高质量、 标准化临床、认知、脑脊液 (CSF)、血清/血浆、DNA 和神经影像数据 促进临床前诊断和早期干预方面的转化性阿尔茨海默病（AD）研究。对此 最后，核心对轻度认知障碍（MCI）患者进行全面的临床评估， AD 引起的轻度痴呆、认知正常的老年对照（OCN，>65 岁）和中年成人（IMPACT 队列（45-65 岁），根据家族史具有不同程度的痴呆风险。临床核心团队的工作 与所有核心密切合作，通过参与外展和招聘活动来促进中心的使命 多元化的社区；对核心参与者进行标准化临床和认知评估；采集 与衰老相关的辅助认知和临床数据，包括详细的血管风险评估；收集高 优质血液、脑脊液和 DNA 生物样本；协调生物样本采集与神经影像学；完成 及时规范数据报送；进行皮肤活检以获得诱导多能性 干细胞（iPSC）系；同意核心参与者进行脑部尸检；促进认知测试和脑脊液 研究者发起的研究中的收集；并确保参与者、数据和信息的及时可用性 向本地及其他地区的研究人员提供生物样本。在下一个拨款周期中，核心将完成以下任务 目标：目标 1：继续招募和留住认知能力未受损的成年人（IMPACT 和 OCN）和患者 与 MCI 进行详细的年度（MCI、OCN）或每两年一次（IMPACT）临床评估（包括标准化 统一数据集 [UDS] 数据和血液样本）以及两年一次（MRI、CSF）和基线（子集中的 PET） 生物标志物评估支持临床前痴呆症的转化研究。目标2：继续招募和 保留因 AD 导致的轻度痴呆患者进行详细的年度临床和血液生物标志物评估 （包括标准化 UDS 数据）和可选的附加基线生物标志物评估（MRI、CSF、PET）。 目标 3：继续将根据文化定制的外展、教育和临床服务整合到不同的人群中 社区提高对大脑健康的认识并鼓励长期研究参与（包括 临床和生物标志物评估）以及在代表性不足的少数群体社区中的宣传。目标 4：继续 获得脑捐赠同意书以支持临床病理研究并收集脑脊液、血液、DNA 和 iPSC 用于 MCI 和 AD 痴呆临床前标志物的转化研究。目标 5：继续提供 基础设施、资源和服务，以促进正常认知衰老、临床前的合作研究 痴呆症和 AD 引起的痴呆症，并加快与国家阿尔茨海默病中心共享数据和资源 协调中心、国家阿尔茨海默病细胞存储库以及其他 AD 中心和研究人员。